Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Human IL-4 Receptor Used in Treatment of Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~Patients may be eligible for this study if they:~* Are 12 to 85 years of age (consent of parent or guardian required if under 18 years).~* Have continuous asthma and are being treated with albuterol MDI only.~* Have reduced lung functions.~* Have a positive reaction to 2 substances as demonstrated with a skin test.~* Have been a nonsmoker for at least 2 years and have not smoked more than 1 pack a day for 5 years or less.~* Agree to use contraception throughout the study.~* Agree not to donate blood throughout the study.~* Are able to use correctly an aerosol drug delivery device.~* Have had an asthma attack on at least 3 of the last 7 days.~Exclusion Criteria~Patients will not be eligible for this study if they:~* Had asthma requiring hospitalization within 6 weeks of beginning study treatment.~* Had asthma requiring emergency room treatment within 12 months of beginning study treatment.~* Had a respiratory infection that affected asthma within 2 weeks of beginning study treatment.~* Had a breathing tube inserted for asthma treatment within 15 years of beginning study treatment.~* Were previously enrolled in a study of soluble IL-4 receptor.~* Have drug abuse, alcohol abuse, or a mental illness that may interfere with the study.~* Have serious medical problems (such as heart or lung problems, uncontrolled high blood pressure, are overweight to the extent that ability to breathe is affected, or have cancer other than skin cancer), diabetes, autoimmune diseases, or HIV.~* Are pregnant or breast-feeding.~* Have used certain drugs.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 0.75mg rsIL-4R (Type: EXPERIMENTAL): Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
- 1.5mg rsIL-4R (Type: EXPERIMENTAL): Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
- 3.0mg rsIL-4R (Type: EXPERIMENTAL): Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
- Placebo for rsIL-4R (Type: PLACEBO_COMPARATOR): The placebo for recombinant human soluble IL-4 receptor (rsIL-4R) consisted of identically prepared excipient in the same volume (2.5 mL). To maintain blinding, medication was dispensed by an individual who was not responsible for patient care or assessment. Treatment assignment was blinded to all personnel involved in direct conduct or monitoring of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete